Cladribine is under development for the treatment of neurological diseases including neuromyelitis optica and neuromyelitis optica spectrum disorder, myasthenia gravis (MG). It is administered through ...

Efgartigimod alfa is under clinical development by Argenx and currently in Phase II for Guillain-Barre Syndrome.

VYVDURA was also approved by the MHLW for manufacturing and marketing in January 2024 and launched in April 2024 for the treatment of generalized myasthenia gravis (gMG). In March 2024, VYVDURA was ...

VYVDURA is now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP. argenx's VYVGART and VYVDURA portfolio was approved in Japan for three indications first ...